Elanco Animal Health Incorporated — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 23.06 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 11.52B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
Details
| Name | Elanco Animal Health Incorporated |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 9900 |
| Founded | 1954 |
| Ipo Date | 2018-09-20 |
| Ceo | Jeffrey Simmons |
| Country | United States |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US28414H1032 |
| Cusip | 28414H103 |
| Cik | 0001739104 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Jeffrey N. Simmons | President, Chief Executive Officer and Director |
| Robert M. VanHimbergen | Executive Vice President and Chief Financial Officer |
| Dr. Ramiro Martin Cabral | Executive Vice President and President of Elanco International |
| Dr. Ellen de Brabander Ph.D. | Executive Vice President of Research, Development and Regulatory Affairs |
| Timothy J. Bettington | Executive Vice President of Center of Strategic Growth |
| James M. Meer | Senior Vice President and Chief Accounting Officer |
| David S. Kinard | Executive Vice President of Human Resources, Corporate Communications and Administration |
| Shiv O'Neill | Executive Vice President, General Counsel and Corporate Secretary |
| Larbi Van Lier | Senior Vice President of Asia |
| Prof. Shabbir Simjee | Chief Medical Officer |
Contact
| Address | 450 Elanco Circle, Indianapolis, Indiana 46221, United States |
| Phone | 877 352 6261 |
| Website | https://www.elanco.com |